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Aim: For vaccines the combination between an antigen and adjuvants are both crucially important to
trigger an effective immune response in dendritic cells. Innovative adjuvants like resiquimod or mu-
ramyldipeptide have their target protein inside the cell. Materials & methods: Up/downregulation and
proteome expression was investigated for the adjuvant combination resiquimod and muramyldipeptide
in a soluble form versus encapsulated into a nanocarrier. Results:We found that 1225 genes were upregu-
lated after nanocarrier treatmentwhile 478 genes were downregulated.Most prominent were interferon-
stimulated genes with more than 25-times higher expression after nanocarrier treatment, for example
RSAD2 and ISG15, which were recently found to have antiviral or antitumor effects. Conclusion: Encapsu-
lation gives a more effective upregulation of vaccine-related genes.
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Even today, the cellular processes triggered by a vaccine leading to the well-known long-term protection are highly
complex and not completely deciphered. Antigen and adjuvants are co-administered as two components. Each
component is recognized independently and evokes distinct effects in the associated cell or tissue. Dendritic cells
(DCs) are the key players for taking up and processing vaccine components. The recognition of the adjuvant via
specific receptors activates the DCs, while the antigen is intracellularly processed and thereafter, presented to the
surrounding cells. The combined effect of both components in the DC is essential for a successful vaccination. Both
components are commonly not coupled chemically nor physically. While some of the adjuvants are recognized
by cell surface receptors, others need to get into the endosome or the cytoplasm of the cell. After injection, they
diffuse independently from each other through the tissue and need to reach and cross into the DC independently.
In contrast, the application of vaccines via a nanoparticular formulation, for instance a nanocapsule (NC), enables
a coupled delivery of antigen and adjuvant into the same target cell. The NC uptake mediates the delivery of
both components. While the antigen always needs to be endocytosed, some of the more interesting adjuvants also
have an intracellular target receptor. Moreover, NCs offer the potential to add diverse chemical modifications, for
instance for DC targeting. While a lot of work has been done to compare the effects of common (soluble) versus
encapsulated vaccines, the transcriptome, in other words the complete mRNA expression profile of such treated
DCs was rarely taken into account to understand the actual impact of encapsulated vaccine.
In this study, we used ovalbumin (OVA)-based NCs (OVA-NCs) with an aqueous core as delivery system as well
as antigen source to treat murine bone marrow-derived DCs (BMDCs). In previous studies, the uptake kinetics
and the controlled payload release of these OVA-NCs have already been investigated in murine [1] and human [2]
DCs. Additionally, these capsules (OVA-Adj-NCs) have already been loaded with the adjuvant combination
muramyldipeptide (MDP) and resiquimod (R848) and used as nanovaccine. It was shown that DC treatment with
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OVA-Adj-NCs induced a synergistic DC activation and thus an effective T-cell stimulation [1]. Additionally, it was
proven that the NCs were more efficient than the soluble application of the respective components in equimolar
amounts. In literature, there is limited information about the overall transcriptional effects of specific adjuvants
or delivery systems. With some exceptions, such as protamine–RNA complexes, CpG-P [3], or heparan sulfate [4],
the transcriptional adjuvant effect is rarely in the focus of vaccination studies. At least, soluble R848 was shown to
trigger an increased mRNA expression of IL-6, IL-12α and IL-12β upon BMDC stimulation for 4 h [5]. Moreover,
transcriptional changes in BMDCs treated with E2 and fd filamentous bacteriophages, two promising delivery
systems, were also investigated [6].
Here, we analyzed the transcriptome of BMDCs incubated with OVA-Adj-NCs by RNA-Seq. In this way, we
were able to determine mRNA expression patterns characterizing the combined delivery of an antigen and adjuvants
via a nanocarrier. These data provide insight into the immunological properties of nanocarriers used for vaccination.
Additionally, it gives a deeper understanding about the differences for a nanocarrier based vaccine delivery system in
comparison with a soluble vaccination approach. Moreover, proteomic analysis gave additional information about
the cellular processes after nanocarrier treatment. At last, this is the first study, which analyzes the transcriptome
of BMDCs with RNA-Seq. Although many literature reports investigated BMDCs in immunological studies, only
gene microarray or quantitative polymerase chain reaction (qPCR) analyses were performed for selected genes [7,8].
Materials & methods
Synthesis of OVA NCs
As previously described OVA-NCs were synthesized in the same procedure and therefore the method can also be
found in [1]. We sum up the method here again: In 500 μl sterile, deionized water 50 mg OVA (grade VI, Sigma-
Aldrich, Deisenhofen, Germany) was dissolved with 7.14 mg NaCl. To this aqueous phase, 13 nmol Cy5-labeled
oligonucleotides (cyanine5-5′- CCA CTC CTT TCC AGA AAA CT, IBA GmbH, Go¨ttingen, Germany) were
added. Afterward 35.8 mg of the surfactant P([E/B]-b-EO) were dissolved in 7.5 g of cyclohexane (VWR, PA,
USA). P([E/B]-b-EO) consists of a poly(ethylene-co-butylene) block and a poly(ethylene oxide) block [9]. Under
stirring, we then added this to the aqueous phase. The pre-emulsion was homogenized by ultrasonication. In a
separate vial, 10.7 mg P([E/B]-b-EO) were dissolved in 5 g of cyclohexane and 2 mg 2,4-toluene diisocyanate
(Sigma-Aldrich). This mixture was then added dropwise to the obtained mini-emulsion. The reaction was allowed
to proceed for 24 h at 25◦C. The samples were further processed by repetitive centrifugation and replacement of
the supernatant with fresh cyclohexane. This removed the excess surfactant from the obtained NCs. Six hundred
microliters of the dispersion from cyclohexane were added dropwise to 5 ml of a 0.1 wt-% aqueous SDS (Alfa
Aesar, Heysham, UK) solution. By this the NC were transferred to water. During transfer the aqueous solution
was placed in an ultrasound bath. In order to evaporate cyclohexane the sample was stirred with an open cap
overnight. Via four centrifugation steps and replacing the supernatant with sterile, deionized water excess SDS
was removed. R848 and MDP (Invivogen, Toulouse, France), 70 μl R848 (10 mg/ml in DMSO) and 250 μl
MDP (10 mg/ml in water) were encapsulated in the respective preparations as indicated. In order to maintain
500 μl of total volume, the amount of water was reduced to end up with the same endvolume. The ultrasonication
device was a Branson Sonifier W-450-Digital (CT, USA) equipped with a microtip. Sonication parameters were
as followed: 3 min at 70% amplitude with a pulse of 20 s sonication and 10 s pauses in between. By dynamic
light scattering, we determined the average size and size distribution of the NCs. The measurements were done at
25◦C with a Nicomp 380 submicron particle sizer (Nicomp Particle Sizing Systems, FL, USA) measuring at fixed
angle of 90◦. ζ potential was done in 10-3 M potassium chloride solution at pH 6.8 and 25◦C by using a Malvern
Zeta sizer (Malvern Instruments, Herrenberg, Germany). Before usage, all OVA-NC batches were analyzed for
endotoxin contamination by limulus amebocyte lysate assay (Thermo Fisher Scientific, MA, USA) according to the
manufacturer’s instructions. Based on the US FDA’s ‘Guidance for Industry: Pyrogen and Endotoxin Testing,’ the
endotoxin limit was to set 0.5 EU/ml. OVA-NC batches with higher endotoxin concentrations were not used for
cellular experiments.
Quantification of encapsulated MDP & R848
As previously described the content of the NCs concerning MDP and R848 were analyzed with the same procedure
as published before and therefore the method can also be found in [1]. We sum up the method here again:
with a centrifugal filter with molecular weight cutoff of 100 kDa (Merck Millipore, Darmstadt, Germany), the
supernatants of the NC dispersions were separated from the capsules themselves. The pellet was redispersed in
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phoshate-buffered saline (PBS) containing 2 mg/ml of trypsin. These were incubated for 24 h. The absorbance at
λ = 325 nm for R848 was used to determine the concentration of R848. This was done on a Lambda 16 UV–Vis
spectrometer (Perkin Elmer, MA, USA). A calibration curve in the range of 0.01–1 mg/ml was used to determine
the concentration of R848. As MDP has no characteristic adsorbance, we needed to use modified MDP by an
Alexa Fluor 488 5-SDP ester. This was done following the manufacturer’s instructions (Thermo Fisher Scientific).
The amount of MDP-Alexa 488 was determined by using a plate reader (Excitation 498 nm, Emission 519 nm).
The calibration curve was determined in a range of 0.34–2.26 μg.
Mice
C57BL/6 mice were bred and maintained in the Translational Animal Research Center of the University Medical
Center Mainz under pathogen-free conditions on a standard diet. The recommendations of the Guide for the Care
and Use of Laboratory Animals by the National Institutes of Health were followed.
Generation of murine BMDCs
BMDCs were differentiated from bone marrow progenitors of 8–10-week-old C57BL/6 mice as described by Bros
et al. [10]. Under sterile conditions, iliac crests, femora and tibiae were prepared from C57BL/6 mice, cleaned
with 70% ethanol and transferred to IMDM containing 5% fetal calf serum (FCS) (both from Sigma-Aldrich)
and 50 μM β-mercaptoethanol (Roth, Karlsruhe, Germany). Bones were sliced and rinsed with a small cannula
to wash out the bone marrow. Bone marrow cells were separated with a 40-μm cell strainer (Greiner Bio-One,
Frickenhausen, Germany) and centrifuged for 10 min at 4◦C and 300×g. Then, 2 × 106 cells were transferred
to a petri dish in 10 ml IMDM containing 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin
(all from Sigma-Aldrich) and 50 μM 2-mercaptoethanol, supplemented with 5% GM-CSF containing cell culture
supernatant derived from X63.Ag8-653 myeloma cells stably transfected with a murine GM-CSF expression
construct [11]. After 3 and 6 days, respectively, 5 ml medium containing GM-CSF was added to the petri dish. On
day 7 or 8, nonadherent DCs were harvested by gentle rinsing. Cells were transferred to six-well plates for further
experiments.
DC treatment with adjuvants/NCs
A total of 2 × 106 BMDCs/well were seeded into six-well plates in 1 ml IMDM containing 2 mM L-glutamine,
5% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin and 50 μM β-mercaptoethanol as well as GM-CSF as
mentioned before. The next day, cells were treated with 75 μg/ml NCs. Here, either OVA NCs loaded with
both R848 and MDP, or empty OVA NCs as control were added to the cells for 1, 2 and 4 h. For comparison,
further BMDC samples were treated with soluble R848 (83.25 ng/ml) andMDP (287.25 ng/ml) in concentrations
equimolar to encapsulated adjuvants, also for 1, 2 and 4 h.One set of BMDCswas left untreated as a negative control
reference. Each treatment was carried out in duplicates. Afterward, samples of the different time points were pooled
and total RNA was extracted via RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
recommendations. RNA quality was analyzed via agarose gel electrophoresis and Bioanalyzer (Agilent Technologies,
CA, USA). RNA quantity was determined via NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific).
Afterward, total RNA was handed over to StarSeq (Mainz, Germany) for subsequent Illumina Next Generation
Sequencing.
Illumina sequencing
cDNA library preparation and Illumina Next Generation Sequencing were carried out by StarSeq. Thereafter,
mRNAs were sequenced via Illumina NextSeq 500™ (Illumina, CA, USA). Overall, at least 25 million paired-end
reads were created per sample (2 × 150 nt, 3.75 Gb) for the eight datasets (two untreated samples, two samples
treated with empty OVA-NCs, two samples treated with MDP/R848-loaded OVA-NCs, two samples treated with
soluble MDP/R848). Data were received in .fastq format.
Quantification of RNA-seq datasets
Obtained next-generation sequencing (NGS) datasets were quantified using the software Geneious R8 (Biomatters,
New Zealand). First, NGS files were imported in .fastq format. Then, paired-end reads were assigned to each other,
whereat the distance was set to 470 bp. The annotated genomic murine reference sequence was obtained by NCBI
(GFF GCF 000001635.25 GRCm38.p genomic.gff ) and imported into the software. Finally, all datasets were
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mapped against the murine reference sequence. For this purpose, all 21 annotated murine chromosomes as well
as the annotated murine mitochondrial DNA were used as reference sequences for the mapping to create contigs
and for contigs quantification by using the Geneious R8 function ‘Calculate expression levels’ by using defined
parameters (Supplementary Table 1).
Then, expression data were transferred to an MS Excel sheet and differences in gene expression were quantified
using the transcripts per kilobase million (TPM) values. Finally, also the ratios of TPM values of the different
sample conditions were calculated (whereat the negative control was set as ‘1’). These ratios were subsequently used
to visualize expression differences via heat maps and scatter plots.
Quantitative PCR
All cDNAs for qPCR were synthesized with the iScript™ cDNA Synthesis Kit (Bio-Rad, CA, USA) according to
the manufacturer’s protocol. Standard 20 μl cDNA synthesis consisted of the components 5X iScript Reaction
Mix (4 μl), iScript Reverse Transcriptase (1 μl), the RNA template (1–100 ng) and nuclease-free water (to 20 μl).
cDNA reactions were briefly mixed by pipetting up and down and then transferred to theMastercycler EP Gradient
S (Eppendorf, Germany) for cDNA synthesis (Supplementary Table 2). For quantitative real time PCRs, specific
qPCR primers (Supplementary Table 3) were designed for the amplification of approximately 200 bp DNA
fragments.
Standard 20 μl amplification reaction consisted of the components iQ SYBR Green Supermix (10 μl), F-Primer
(1 μl), R-Primer (1 μl), cDNA template (3 ng) and nuclease-free water (to 20 μl). All ingredients were mixed gently
by pipetting up and down and then transferred to the real time system CFX96 (Bio-Rad) for cyclic amplification
and measurement of SYBR Green dye (Supplementary Table 4). Finally, gene expression was calculated by using
the Ct-method [12]. GAPDH was used as a reference gene. The melt curve was analyzed manually for successful
amplification of target DNA fragments.
Liquid chromatography coupled to mass spectrometry
Protein extraction and digestion was carried out as previously published [13,14]. Briefly, cells were dissolved in lysis
buffer containing 7 M urea, 2 M thiourea, 2% CHAPS and incubated for 15 min at 37◦C and centrifuged for
1 h (4◦C 20.000×g). Further, the supernatant was transferred into a 1.5 ml protease-free tubes and the protein
concentration was determined by Pierce™ 660 nm Protein Assay Kit (Thermo Fisher Scientific) according to the
manufactures’ instructions.
Extracted proteins were precipitated overnight using ProteoExtract protein precipitation kit (Cal-
BioChem, Darmstadt, Germany) according to the manufactures’ instructions and resuspend in RapiGest SF
(Waters Cooperation, Eschborn, Germany) dissolved in ammonium bicarbonate (50 mM) buffer. Samples were
incubated at 80◦C for 15 min, reduced with dithithreitol (Sigma-Aldrich, 5 mM, 45 min, 56◦C) and alkylated
with idoacetoamide (Sigma, 15 mM, 1 h, room temperature [RT]). For digestion a protein: trypsin ratio of 50:1
over 16 h at 37◦C was used. The reaction was quenched hydrochloric acid (Sigma).
Peptide samples were diluted with 0.1% formic acid and spiked with 50 fmolμl-1 Hi3 Ecoli (Waters Cooperation)
standard for absolute protein quantification [15]. Proteomic measurements were performed with a nanoACQUITY
UPLC system coupled with a Synapt G2-Si mass spectrometer. A NanoLockSpray source was used for electrospray
ionization in positive ion mode and the Synapt G2-Si was operated in resolution mode. Data were acquired and
processed with MassLynx 4.1 was used. Proteins were identified with Progenesis QI (2.0) using a reviewed human
data base (Uniprot). Processing parameters were set as described in previous reports [16,17]. The amount of each
protein was determined in fmol based on the TOP3/Hi3 approach [18].
Results
NC characterization
All OVA-NC formulations were produced in inverse mini-emulsion using cyclohexane as continuous phase [2].
After purification and transfer of the OVA-NCs into water, cyclohexane was efficiently removed as shown by
1H-NMR measurements (Supplementary Figure 1). The diameter of the empty OVA-NCs was determined to
be 256 nm in cyclohexane and 348 nm after transfer into water. Their ζ potential was -26 mV. The adjuvant-
loaded OVA-NCs showed a diameter of 302 nm in cyclohexane, 338 nm in water and a ζ potential of -31 mV
(Supplementary Table 5) Diameters of the experimentally used OVA-NCs in cyclohexane and water as well as the
ζ potential were measured via dynamic light scattering. Data were previously shown in [1]. Encapsulated MDP and
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R848 were measured via fluorescence spectroscopy. Adjuvant loading was determined to be 7.14 nmol MDP (with
an encapsulation efficiency of 73.6%) and 2.85 nmol R848 (with an encapsulation efficiency of 65.9%) per mg
NC (Supplementary Table 6). Characterization of the used OVA-NCs (± adjuvants) has already been described in
a previous publication [1].
Besides all this, the adjuvant loading capacities of OVA-NCs and the resulting encapsulation efficiencies were
measured and calculated to determine the amount of MDP and R848 per mg OVA-NC, and to be able to
analyze how much adjuvant is actually available during cellular treatment. It turned out that MDP showed higher
encapsulation efficiency in OVA-NCs than R848, most likely due to its better solubility characteristics in water.
In the end, the loading capacity of the OVA-NCs and therefore the encapsulation efficiencies of each adjuvant is
determined and limited by the underlying manufacturing process.
RNA extraction of differently treated DCs
BMDCs were treated with 75 μg/ml OVA-NCs, either empty or loaded with adjuvants, or equimolar amounts of
soluble adjuvants for 1, 2 and 4 h. Afterward, the respective wells containing different time points of incubations
were pooled together prior to RNA extraction to ensure to not miss the optimal time point of transcriptomic
changes after the NC/adjuvant treatment. This was performed for two sets of BMDCs = two biological replicates
for each treatment. Finally, total RNA was extracted, and quality controlled via Bioanalyzer measurements, a
device that provides automated electrophoretic separations. The Bioanalyzer software calculates the RNA Integrity
Number, which is based on the intensity ratios of the 28S rRNA, 18S rRNA and the background signal [19].
Total extracted RNA was around 100–300 ng/μl for each sample (Supplementary Figures 2–9). All RNA samples
featured RNA Integrity Number values of at least 9.4, indicating a high quality. After confirming sufficient quality,
RNA samples were transferred to StarSeq (Mainz, Germany) for mRNA extraction, cDNA library creation, and
Illumina sequencing. By this procedure, a total of 25 million reads with each 150 nucleotides per sample were
obtained in .fastq format, which represents genetic information of >3.7 gb of DNA per sample. All samples were
mapped against the 21 annotated murine chromosomes as well as the annotated murine mitochondrial DNA
sequence. A total number of 76,640 transcripts were detected, corresponding to 22,558 murine genes, which fits
the number of protein-coding genes described in literature [20]. All genes were finally analyzed for their TPM values.
Genes which did not exhibit a TPM value of at least 20 in two or more samples were removed. For the 10,135
remaining genes, we calculated the mean values of the two biological replicates and thus the relative expression
ratios in the NCs-treated samples (± adjuvants) against the untreated control.
Expression of relevant gene groups
The transcriptome of BMDCs treated with 75 μg/ml OVA-Adj-NCs or equimolar amounts of soluble adjuvants
(1, 2 and 4 h pooled) were analyzed by RNA-Seq. As a control we used untreated BMDCs as well as BMDCs treated
with empty OVA-NCs. Transcriptome analysis allows a deeper understanding of the cellular processes that were
initiated by a nanocarrier and its payload. Moreover, we analyzed the differences between soluble and encapsulated
adjuvant delivery.
First of all, the generated gene list was scanned for genes, which could be assigned to defined categories of interest
(Supplementary Box 1). The TPM values of the corresponding genes were used to be able to determine the general
expression level of each gene and to perform a preselection. Furthermore, the relative expression ratios against the
untreated control were analyzed comparatively to identify changes on RNA level triggered by the empty OVA-NCs,
OVA-Adj-NCs or the corresponding soluble adjuvant combination.
Prominent upregulation of interferon-stimulated genes by encapsulated adjuvants
The most prominent differences between soluble and encapsulated adjuvant application on mRNA level were
detectable for the group of interferon(IFN)-stimulated genes (ISGs), which are usually triggered by Type I IFNs [21].
Numerous of those mRNAs were strongly upregulated byOVA-Adj-NCs, whereas the soluble adjuvant treatment as
well as the incubation with empty OVA-NC did not evoke such a tremendous effect. By OVA-Adj-NC treatment
many genes were upregulated by more than 25–30-fold compared with the untreated control. ISGs, such as
RSAD2 and ISG15, were especially prominent. Moreover, both ISGs have already been described to be beneficial
for an effective antitumor immune response. RSAD2 has been reported as a necessary factor for DC maturation
in a B16F10 pulmonary metastasis model [22], while ISG15 has been identified to trigger antitumor immune
responses by promoting intratumoral infiltration of natural killer (NK) cells and enhancing antigen presentation
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Figure 1. mRNA expression ratios of interferon-stimulated genes. The relative mRNA expression ratios of diverse IFN-stimulated genes
of bone marrow-derived dendritic cells (2 × 106 cells/ml) treated with empty OVA-NCs, OVA-Adj-NCs (both 75 μg/ml), or equimolar
amounts of soluble adjuvants were calculated against the untreated control. Dashed line indicates mRNA expression of untreated
control. Tests were performed in duplicate (n = 2).
NC: Nanocapsule; OVA: Ovalbumin.
in tumor cells 25. With some exceptions, such as IFIT3, IFIT3B and IFIT1BL1 for empty OVA-NCs and
IFI205 for soluble MDP/R848, the effect of these two treatments on ISG expression was generally rather weak
(Figure 1). These results indicated that an ISG upregulation is highly dependent on the combined presence of
OVA-NC (representing the antigen) and the adjuvants. Although BMDC stimulation with soluble MDP/R848
triggered a strong transcriptional upregulation of costimulatory molecules and pro-inflammatory cytokines (see
Figure 2A & 3), it was not sufficient to mediate Type I IFN-dependent ISG upregulation. A highly increased
mRNA expression of IRF7 upon treatment with OVA-Adj-NCs, but noticeably weaker with empty OVA-NC or
equimolar amounts of soluble adjuvants (Supplementary Figure 10) underlines our results, since IRF7 is a crucial
regulator of Type I IFNs in pathogenic infections [23].
Up/downregulation of costimulatory & DC markers
Costimulation is a major requirement for an adaptive DC-mediated immune reaction. Focusing on the corre-
sponding genes in BMDCs, we observed an increased expression for CD40, CD80, CD83 and CD86 mRNA as
well as for TNFSF4 (OX40L) and ICAM1 after treatment with MDP/R848-loaded OVA-NCs compared with the
untreated control and those treated with empty OVA-NCs. In case of equimolar amounts of soluble adjuvants, the
expression of only CD40 and ICAM1 were noticeably influenced. The further costimulatory marker mRNAs of
this treatment showed expression levels similar to those of the empty OVA-NC sample (Figure 2A). These results
were consistent with our previous measurements of costimulatory molecule expression on protein level upon treat-
ment with OVA-Adj-NCs [1]. In this case, the encapsulated delivery of MDP and R848 via OVA-NCs enhanced
their stimulatory potential to trigger mRNA expression of costimulatory molecules in BMDCs compared with the
soluble application.
In contrast, theNC or the soluble adjuvant treatment did not influence the expression of typical DCmarker genes
such as ITGAX (CD11c). Compared with the untreated control, the expression of ITGAX (CD11c) and ITGAM
(CD11b) was actually decreased upon incubation with OVA-MDP/R848-NCs (Figure 2B). Downregulation of
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Figure 2. mRNA expression ratios of costimulatory molecules and dendritic cell markers. The relative mRNA expression ratios of (A)
costimulatory molecules and (B) dendritic cell markers of bone marrow-derived dendritic cells (2 × 106 cells/ml) treated with empty
OVA-NCs, OVA-Adj-NCs (both 75 μg/ml), or equimolar amounts of soluble adjuvants were calculated against the untreated control.
Dashed line indicates mRNA expression of untreated control. Tests were performed in duplicate (n = 2).



































































































































































Figure 3. mRNA expression ratios of cytokines. The relative mRNA expression ratios of cytokines of bone marrow-derived dendritic cells
(2 × 106 cells/ml) treated with empty OVA-NCs, OVA-Adj-NCs (both 75 μg/ml), or equimolar amounts of soluble adjuvants were
calculated against the untreated control. Y-axis is visualized in logarithmic scale. Dashed line indicates mRNA expression of untreated
control. Tests were performed in duplicate (n = 2).
NC: Nanocapsule; OVA: Ovalbumin.
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CD11c [24] andCD11b [25] have been described to be associated with DC stimulation. Therefore, the results indicate
a more extensive stimulation in case of encapsulated application compared with soluble.
Upregulation of cytokines is only slightly different between soluble & encapsulated adjuvants
Cytokines as an elemental component of every immune reaction were also analyzed by RNA-Seq. Cytokine mRNA
expression analysis showed that empty OVA-NCs induced only a decent increase in the mRNA expression of IL1A,
IL6, IL12A, IL12B and TNF, while the expression levels of IL1F6, IL10, and particularly IL23A were noticeably
upregulated. The resulting IL-23 belongs to the pro-inflammatory IL-12 family and is known to support Th17
differentiation [26]. Compared with this, BMDC treatment with OVA-Adj-NCs as well as soluble adjuvants evoked
a strong increase in the mRNA expression of numerous, but almost the same cytokines. In this regard, the soluble
adjuvant treatment showed in many cases higher expression ratios than the OVA-Adj-NC treatment, for instance
for IL23A, IL1A and TNF. Nonetheless, some cytokines, such as IL12A and IL1F6, were more upregulated by the
encapsulated adjuvants. In comparison with the untreated control, both adjuvant treatments triggered specific, but
comparable cytokine patterns (Figure 3). Again, the results agreed with previous ones showing increased secretion
of IL-1β, IL-6, TNF-α and IL-12 upon treatment with OVA-Adj-NCs. Particularly interesting was the strong
upregulation of IL12A compared with the soluble adjuvant treatment, since it is necessary to form a functional
IL-12. In contrast, the soluble adjuvants triggered higher amounts of TNFmRNA. Nonetheless, we have previously
shown thatOVA-Adj-NC-treated BMDCproduce both IL-12 andTNF-α in high amounts [1]. Except IL10mRNA,
which encodes for the anti-inflammatory IL-10, only pro-inflammatory cytokine mRNAs were upregulated upon
stimulation with MDP + R848, whether soluble or encapsulated.
MHC appears to be slightly overexpressed for encapsulated adjuvants
Analysis of the relative mRNA expression ratios of different MHC-I andMHC-II molecules in BMDCs revealed an
increased expression of some prominent MHC-I molecules, such as H2-Q10 and H2-Q4, as well as of the MHC-
I base component β2 microglobulin (B2M) upon treatment with OVA-Adj-NCs compared with the untreated
control. Even though a slight increase of those molecules was detectable after BMDC incubation with empty OVA-
NC and soluble adjuvants, it was in both cases considerably weaker compared with the first-mentioned treatment.
Regarding MHC-II molecules, only H2-Eb2 mRNA was upregulated upon treatment with empty OVA-NCs and
OVA-Adj-NCs. Application of soluble adjuvants did not show any effect in this context (Figure 4).
Up/downregulation of chemokine expression
Regarding chemokine mRNAs, we observed complex expression patterns induced by all three treatments compared
with the untreated control. Thereby, numerous mRNAs were upregulated specifically by both adjuvant treatments,
such as CCL1, CXCL5 or CCL4, while CXCL9, CXCL10 and CCL1 mRNA expression was also stimulated by
empty OVA-NCs. While the expression of the chemokines CXCL1, CCL1 and CXCL2 was more triggered by
soluble MDP/R848, CXCL9 and CXCL10 mRNA expression was much more enhanced by OVA-Adj-NCs. This
resulted in relative expression ratios of more than 50 compared with untreated cells (Figure 5).
Up/downregulation of other groups of genes
Besides these striking results, further gene groups revealed distinct effects triggered byOVA-Adj-NCs and the soluble
adjuvant combination, respectively. Regarding TLRs/NLRs and scavenger receptors, increased amounts ofNLRP3,
TLR2, TLR7 and TLR8mRNAs were detectable upon treatment with soluble MDP/R848 (Supplementary Figure
11), whereas the transcriptional expression of CD14 and MARCO was enhanced by both (Supplementary Figure
11). While TLR and NLR expression highly depends on specific cell type and maturation state [27], CD14 as well
as MARCO have already been described to be upregulated in DCs by successful stimulation [28,29]. In contrast,
mRNA expression of the C-type lectin LY75 (DEC-205), which is highly associated with the expression of CD8α
in lymphoid DCs [30], was upregulated (2.4-fold) in BMDCs, when they were treated with OVA-Adj-NCs but
not with soluble adjuvants (Supplementary Figure 12). Another parameter to assess effective DC maturation is
the expression profile of chemokine receptors. BMDC treatment with OVA-Adj-NCs evoked a transcriptional
upregulation of CXCR5 as well as CCR7. In contrast, the stimulation with soluble adjuvants did not change the
mRNA expression of these two receptors at all. Empty OVA-NCs only triggered slight increases of both. At the
same time, the mRNA expression of the chemokine receptors CCR1, CCR2 and CCR5 was downregulated by the
adjuvant-loaded OVA-NCs but not by the soluble adjuvants (Supplementary Figure 13). Interestingly, an increased
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Gene Untreated OVA-NCs Sol. Adj OVA-Adj-NCs
MHC-I





































































































Figure 4. mRNA expression ratios of MHC-I/-II molecules. The relative mRNA expression ratios of (A) MHC-I and (B)
MHC-II molecules of bone marrow-derived dendritic cells (2 × 106 cells/ml) treated with empty OVA-NCs,
OVA-Adj-NCs (both 75 μg/ml) or equimolar amounts of soluble adjuvants were calculated against the untreated
control. Dashed line indicates mRNA expression of untreated control. Tests were performed in duplicate (n = 2).





















































































































































































Figure 5. mRNA expression ratios of chemokines. The relative mRNA expression ratios of chemokines of bone
marrow-derived dendritic cells (2 × 106 cells/ml) treated with empty OVA-NCs, OVA-Adj-NCs (both 75 μg/ml) or
equimolar amounts of soluble adjuvants were calculated against the untreated control. Y axis is visualized in
logarithmic scale. Dashed line indicates mRNA expression of untreated control. Tests were performed in duplicate
(n = 2).
NC: Nanocapsule; OVA: Ovalbumin.
expression of CXCR5 and CCR7 combined with decreased amounts of CCR1, CCR2 and CCR5 has been defined
by Oppenheim et al. as characteristics of fully-matured DCs [31,32]. The transcriptional chemokine receptor profile
of OVA-Adj-NC-treated BMDCs closely matched these specifications, while those treated with soluble adjuvants
or empty OVA-NCs did not. As an internal control, the mRNAs of 19 housekeeping genes were measured. As
expected, no transcriptional alterations were detectable for the different treatments (Supplementary Figure 14).
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Figure 6. Relative transcriptome changes
of differently treated bone
marrow-derived dendritic cells versus
untreated control. Mean values of the two
biological replicates were calculated and
the relative expression ratios of bone
marrow-derived dendritic cells (2 × 106
cells/ml) treated with either empty
OVA-NCs, muramyldipeptide/
resiquimod-loaded OVA-NCs (both
75 μg/ml) or equimolar amounts of soluble
muramyldipeptide/resiquimod
(287.25 ng/ml/83.25 ng/ml) against the
untreated control were determined for
each gene. Y-axis is visualized in
logarithmic scale. Each dot represents one
gene. Tests were performed in duplicate
(n = 2).
NC: Nanocapsule; OVA: Ovalbumin.
Overall gene expression upon treatment
The overall increase in gene expression was analyzed with a threshold factor of at least 1.5. Under these rules, the
expression of 418 genes was identified to be increased after treatment with soluble MDP/R848. The treatment with
the empty OVA-NCs resulted in an upregulation of 518 genes. Interestingly, the combination of both, meaning
MDP/R848-loaded OVA-NCs, triggered an increase of 1225 genes. The same tendency was observed for tran-
scriptomic downregulation upon treatment (threshold factor of at least 0.5). Cells treated with soluble MDP/R848
revealed 161 downregulated genes, whereas cells treated with empty OVA-NCs showed 45 downregulated genes.
In contrast, the expression of 478 genes was identified to be decreased after treatment with MDP/R848-loaded
OVA-NCs. All changes in the transcriptome of differently treated cells compared with the untreated control were
visualized in a graph (Figure 6). Significantly more genes were upregulated or downregulated upon treatment with
MDP/R848-loaded OVA-NCs than with the soluble equivalents or empty OVA-NCs. Furthermore, many genes
showed a much stronger increase in expression in this sample.
RNA-Seq versus qPCR
Compared with the widely used Sanger sequencing, NGS methods (such as RNA-Seq) as well as qPCR provide
significantly higher but similar analytical sensitivity, specificity and high concordance [33]. To confirm the RNA-Seq
results with an additional method, we picked representative upregulated (IL12B, IRF7, CXCL10 and NOS2) and
downregulated (F2RL2) as well as only slightly influenced genes (CD11c and HSPA8) and determined the relative
gene expression levels by qPCR. The calculated relative copy numbers (untreated was set as 1) of all measured
upregulated genes revealed similar tendencies for the twomethodologies. In case of IL12B, the relative copy numbers
were almost the same, whereas for IRF7 and CXCL10 qPCR results showed higher expressions. In contrast, the copy
numbers for NOS2 were lower for qPCR (Figure 7). A comparison of the relative copy numbers of the mentioned
downregulated and slightly influenced genes via RNA-Seq and qPCR exposed a high level of agreement for the two
result groups. F2RL2, CD11c as well asHSPA8 showed comparable copy numbers (Supplementary Figure 15). Our
qPCR results confirmed those of RNA-Seq. Although the relative copy numbers were not completely comparable,
the general progressions measured by qPCR strongly correlated with those of RNA-Seq.
Quantitative proteomic analysis
As a complementary approach to our transcriptome analysis, we performed a comprehensive proteomic analysis
of the cellular proteome after NC and soluble adjuvant treatment. In parallel to the RNA extraction (as described
above), intracellular proteins were extracted, digested and analyzed via label free high-resolution mass spectrometry.
The absolute amount of each protein in fmol was determined via the TOP/Hi3 approach [18]. We further calculated
the relative ratio of each protein in the treated sample versus untreated cells. All proteins, which were enriched more
than two-times, were classified into eight different protein classes based on their biological function (Figure 8A)
and their relative amount in percent was calculated.
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Figure 7. Comparison of upregulated genes determined by RNA-Seq and qPCR. To verify the RNA-Seq results via
qPCR, bone marrow-derived dendritic cells (2 × 106 cells/ml) were treated with empty OVA-NCs or OVA-Adj-NCs (both
75 μg/ml). The relative mRNA copy numbers of four representative upregulated genes (IL12B, IRF7, CXCL10 and
NOS2) were measured by RNA-Seq and qPCR, and plotted comparatively against the untreated control.
NC: Nanocapsule; OVA: Ovalbumin.
Here, we found that there was a significant difference in the cellular proteome after NC treatment in comparison
with the soluble adjuvants. Proteins involved in the trafficking process and signal transduction are highly enriched
in the cellular proteome after NCs treatment in comparison with the soluble adjuvants. In contrast, we detected
a significant higher amount of cellular proteins involved in the immune response after treatment with the soluble
adjuvants in comparison with the encapsulated ones. A full list of all identified proteins is additionally provided in
a separate Excel sheet.
For a deeper proteomic analysis, a hierarchical cluster analysis was carried out using the web tool ClustVis
(Figure 8B). Most strikingly, we saw that Ras-related proteins or granulins were significantly enriched after NC
treatment. All of these proteins are involved in intracellular membrane trafficking process and endosomal trans-
port [13]. Therefore, these data give insight into the cellular uptake processes of the NCs.
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Figure 8. Analysis of intracellular proteins. Protein classification (A) and hierarchical clustering analysis (B). Bone marrow-derived
dendritic cells (2 × 106 cells/ml) were treated with OVA-Adj-NCs (75 μg/ml) or equimolar amounts of soluble adjuvants. Cellular proteins
were extracted, analyzed by label-free shotgun proteomics and classified into eight different classes based on their biological Proteins,
which are enriched more than two-times, were analyzed with the web tool ClustVis. Tests are performed from a duplicate dataset (n = 2).
MDP: Muramyldipeptide; NC: Nanocapsule; OVA: Ovalbumin; R848: Resiquimod.
In contrast, after treatment with the soluble adjuvant combination, cellular proteins involved in the immune
response, for example protein S100-A8/A9 or H-2 class II histocompatibility antigen were upregulated. Most
interestingly, there was a prominent difference for cells treated with the single adjuvants versus the combined
adjuvants underlining the synergistic effect a specific adjuvant combination. Hence, the strong immunological
response of the encapsulated adjuvant combination was not observed on a protein level. However, for the presented
experiments the incubation time ranged from 1 to 4 h. Therefore, the lower immunological response of the NCs in
comparison with the soluble adjuvants could be caused by differences in the cellular uptake kinetics and intracellular
processing.
Discussion
Demonstrating the effect of adjuvant loaded nanocarriers can be done in a targeted fashion, in other words, looking
at the expression level of selected genes. This is usually done by picking important genes as they have been reported
in literature to be influenced by the specific adjuvant. Unfortunately, this approach is blind toward effects of
adjuvants delivery by nanocarriers and how they enable a better stimulation of some pathways of intracellular
and extracellular signaling. We have demonstrated that a NGS approach gives a clearer and is able to provide an
all-embracing approach. Hereby, a quantitative comparison between encapsulated and nonencapsulated adjuvants
can be achieved.
For all formulations tested, ISGs played a prominent role in our analysis and were highly upregulated for the
encapsulated adjuvants versus the soluble ones. This is an extremely important result as ISGs play a major role in
the immune response. ISGs, such as RSAD2 (33, five-times overexpressed by adjuvant-loaded NCs) and ISG15
(27-times overexpressed by adjuvant-loaded NCs), are especially attributed with an emerging role in antiviral
immunity [34,35]. Moreover, both ISGs have already been described to be beneficial for an effective antitumor
immune response which is important for other projects in the field of antitumor vaccination. RSAD2 has been
reported as a necessary factor for DC maturation in a B16F10 pulmonary metastasis model [22], while ISG15
has been identified to trigger antitumor immune responses by promoting intratumoral infiltration of NK cells
and enhancing antigen presentation in tumor cells [36]. Moreover, Bidwell et al. have identified IRF7 silencing
to promote metastasis in breast cancer [37]. Since ISG expression is defined as a first line of host defense against
virus infections [21], it seems that only the combined application of antigen and adjuvant mimics the presence of
a potential virus-like thread sufficiently in this setup, whereas antigen-NC or superadditive adjuvant combination
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alone fail. Although the transcriptome profiles were striking, the absence of a soluble antigen-only control in RNA
expression levels might be seen as a limitation for our data and should be addressed in future experiments.
It has already been reported by numerous studies that DC stimulation with adjuvants does not only evoke
an increase of costimulatory molecules on protein level but also a transcriptional upregulation [38–40]. Since
costimulatory molecules are highly essential for the induction of DC-mediated T-cell activation [41], increased
amounts of such mRNAs are advantageous if you strive for a strong T-cell response. Our results demonstrate that
a nanocapsular packaging device supports the enhanced intracellular delivery of MDP and R848 toward their
endosomal (TLR7 for R848) or cytoplasmic (NOD2 for MDP) target especially by enhancing the upregulation of
CD40, but also classical markers like CD80, CD83 and CD86 and that nanoencapsulated adjuvants yield a higher
costimulatory effect.
Besides the cell surface markers of costimulation, we investigated the upregulation of cytokines. Here, we found
high upregulation of IL23A and IL12, but with no clear advantage for the nanoencapsulated form. Nevertheless,
cytokines are the most important secondary signal for an efficient vaccination response. IL-12 is the key mediator
of Th1 differentiation, which is highly desirable in tumor vaccination, whereas TNF is controversially discussed
regarding its pro and antitumoral effects [42]. Consequently, IL-12 is of more relevance in this study. It has been
reported by several studies that DC stimulation with different adjuvants not only triggers increased secretion of
proinflammatory cytokines but also an upregulation of those markers, particularly TNF-α, IL-1β and IL-6, on
transcriptional level [38–40]. Moreover, Hotz et al. reported in 2016 that BMDC stimulation with R848 for 4 h
triggered increased mRNA expression of IL6, IL12A and IL12B [5]. IL-10, a major suppressive cytokine, is known to
inhibit MHC-II and CD80/CD86 expression as well as the production of proinflammatory cytokines in DCs [43].
Furthermore, autocrine IL-10 signaling can block IL-12 production [44]. Due to the underlying negative feedback
loop (IL-12 production triggers IL-10) and the result that the mRNAs of the IL-12 subunits IL-12p35 (IL12A) and
IL-12p40 (IL12B) were also upregulated, it was expected to detect elevated levels of IL-10. Interestingly, there are
some cytokines which show a higher relative transcriptional expression upon treatment with the soluble adjuvants
(such as IL1A andTNF) compared with the encapsulated. A possible explanation is that TNF as well as IL1A encode
cytokines which belong to the early stage cytokines, so cytokines which are secreted early in case of an immune
reaction. Since the soluble adjuvants are much earlier available for receptor binding (and thus stimulation) upon
cellular uptake compared with the encapsulated ones (intracellular release required), it is likely that they induce the
transcriptional upregulation of such early stage cytokines earlier. In general, the transcriptional expression pattern
of cytokines upon stimulation over time is a very complex issue. It highly depends on the maturation stage of the
DCs. In total, both the soluble and the encapsulated combination of MDP + R848 triggered strong and highly
similar proinflammatory mRNA cytokine profiles, despite the fact that OVA-NCs have to be degraded first.
Antigen presentation via MHC-I is essential for the induction of cytotoxic T-cell responses, which are important
for an effective tumor fighting. Therefore, an increased expression of according mRNAs might enhance such
responses and result in a better outcome. Most importantly, the nanoencapsulated adjuvants showed here some
effect while the soluble adjuvants did not. As in case of ISGs, also MHC-I-coding genes seem to require both
antigen and adjuvant for a sufficient transcription.
Chemokines in general are responsible for chemotaxis, cell differentiation and the recruitment of specific immune
cells. Here also found striking effects for the nanoencapsulated adjuvants in comparison with the soluble ones. In
particular, CXCL9 and CXCL10 have been reported to be positively associated with tumor suppression [45] and
are, thereby, recognized by the same receptors, namely CXCR3, which is mainly expressed on Th1 T cells and NK
cells upon activation. Furthermore, they have both been described as essential factors inducing the recruitment
and infiltration of tumor-suppressive CXCR3+ T cells and NK cells into solid tumors [46–48]. Consequently, an
increased expression of CXCL9 and CXCL10mRNA by DCs as demonstrated by our results for nanoencapsulated
adjuvants might be promising for potential tumor vaccinations with MDP/R848-loaded protein NCs and may
contribute to a better performance of a nanoencapsulated vaccine with adjuvants.
Besides these groups of genes overexpressed after administration of adjuvants or even better nanoencapsulated
adjuvants, we observed the upregulation of gene expression which were standing alone. For example, DEC-205 was
observed to be upregulated in our study. Butler et al. reported in 2007 that DEC-205 is upregulated upon effective
DC maturation by molecule redistribution and de novo synthesis [49]. In the group of IFN signaling-associated
genes, the mRNA expression of the mentioned IRF7 but also STAT1, STAT2, and to a certain extent IRF1, IRF9
and IRF8 was stimulated more effectively by OVA-Adj-NCs than by the soluble adjuvants or empty OVA-NCs
(Supplementary Figure 10). STAT1 and STAT2 are key mediators of Type I and III IFN signaling, therefore
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important for cellular antiviral responses and the mediation of adaptive immunity [50]. Thereby, they interact with
IRF9 to form the transcription factor ISGF3, which mediates the transcription of numerous ISGs [51]. IRF1 and
IRF8 work in a similar way by binding and triggering IFN stimulated response element promoters in the nucleus,
leading to ISG expression [52,53]. In this regard, the transcriptional upregulation of those essential regulatory IFN
signaling-associated genes upon treatment with OVA-Adj-NCs provides a clear explanation for the massive ISG
mRNA expression.
Conclusion
Altogether, our study demonstrated the induction of numerous immunologically relevant molecules onmRNA level
in BMDCs upon treatment with MDP/R848-loaded OVA-NCs. Thereby, the combined application of antigen
and adjuvant in one nanocarrier triggered a much broader transcriptional response compared with a treatment
with equimolar amounts of soluble MDP/R848 or empty OVA-NCs. In particular, the IFN signaling pathway
associated with ISG expression was massively influenced by the adjuvant-loaded NCs, whereas single application
of OVA-NC and adjuvants, respectively, did not. Interestingly, Type I IFN mRNA (e.g., IFNA1 and IFNB1) was
not detectable in any case, though some of their known repressors, such as SOCS3 [54] or PRDM1 [55], showed an
increased transcriptional expression in the presence of adjuvants. It is known that Type I IFNs underlie a rapid
transcriptional decrease upon induction due to transcriptional repression and mRNA turnover [56]. Moreover, Abe
et al. have reported transient increases and decreases in IFN-β mRNA expression after adjuvant stimulation [57].
We concluded that the delivery of both antigen-NCs and adjuvants was much more efficient in inducing a strong
activation of IFN signaling in this setup, which in turn triggered an increased expression of various ISGs. Since
neither antigen-NCs nor adjuvants alone did so, this effect can only be attributed to the combination of both in
one system. Considering that several ISGs have been described to show antiviral or even antitumor activity, this
might be an important aspect to take into account in future nanovaccine approaches.
Summary points
• The immune response of bone marrow-derived dendritic cell treated with an adjuvant combination resiquimod
and muramyldipeptide in a soluble form versus encapsulated into a nanocarrier was studied by next-generation
sequencing.
• A total of 1225 genes were upregulated after nanocarrier treatment, while 478 genes were downregulated in
bone marrow-derived dendritic cells.
• The combined application of antigen and adjuvant in a nanocarrier triggered a much stronger and broad
transcriptional response compared with a treatment with soluble adjuvants.
• The expression of interferon-stimulated genes was heavily influenced by the adjuvant-loaded nanocapsules (NC)
in comparison with soluble adjuvants or ovalbumin (OVA)-NCs without adjuvants.
• IL-12A and MHC-I and -II were stronger expressed for the encapsulated form while this was not the case for the
soluble application.
• The next-generation sequencing data were verified by qPCR for selected genes.
• The combined application of antigen and adjuvant in a nanocarrier triggered a much broader transcriptional
response compared with a treatment with equimolar amounts of soluble adjuvants or OVA-NCs only.
• The cellular uptake pathway of the nanocarriers of OVA nanocarriers was additionally studied by label-free
shotgun proteomics.
• A comprehensive overview about immunological properties of nanocarriers used for vaccination is presented to
evaluate their in vivo efficacy.
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